A healthcare company trying to launch a new headache curing drug. Should or shouldn't they invest when they already have a general painkiller in the market
Back to overview
18
How would I approach this? Possible Framework?
2
4.4k
Be the first to answer!
Nobody has responded to this question yet.
Top answer
Vlad
edited on Jun 05, 2018
Coach
McKinsey / Accenture Alum / Got all BIG3 offers / Harvard Business School
Hi,
Hi,
I recommend starting with clarifying the objective - Which metrics you need to achieve with the product? Most probably it will be ROI.
I would also clarify whether it's our painkiller on the market or the product of the competitors since competition and cannibalization are the two different cases. Then I will follow up with the structure:
Analyze our product:
- The value proposition of a product compared to the painkiller
- Different use cases of a product compared to the painkiller
- Unit economics (Current unit costs and costs in relation to scale, Investments, ROI targets, Competitor / substitutes pricing)
- Key capabilities to compete (Patent, distribution, etc)
Analyze the market:
- Size and growth rates of the painkiller market
- Size and growth rate of headache drugs
- Regulation - are they both OTC? Prescribed? Is it different by geography?
Analyze the competitors:
- Market shares, growth rates, profits
- Product (Value proposition)
- Unit economics (Value proposition vs. price vs. costs)
- Key capabilities (Distribution, supply, assets, knowledge, etc)
investment decision:
- Costs, benefits, and investments
- ROI
- Risks
Best!
0 comments
Sidi
on Jun 05, 2018
Coach
McKinsey Senior EM & BCG Consultant | Interviewer at McK & BCG for 7 years | Coached 500+ candidates secure MBB offers
Hi Anonymous,
the new drug should be launched if the net value associated with this move exceeds the investment cost over the client's target investment horizon. Morover, Risk needs to be manageable.
So you have 4 buckets to investigate:
- Net value (expected profits of new drug + impact on profits of current painkiller (potential cannibalization!))
- Investment Horizon
- Investment need for launch of the new drug
- Wider risks associated with the new drug (regulation? competitive responses? consumer sentiment?...)
Cheers, Sidi
Sign up for free to read all answers.
Sign up for free to read all answers.
Similar Questions
Most Popular Posts
Are consulting exit opportunities driven more by firm prestige or industry expertise?
8
on Feb 12, 2026
Global
8
100+
Top answer by
Alessandro
Coach
McKinsey Senior Engagement Manager | Interviewer Lead | 1,000+ real MBB interviews | 2026 Solve, PEI, AI-case specialist
8 Answers
100+ Views
E
+5
Non-traditional candidate re-applying to the GCC
10
on Feb 13, 2026
Middle East
6
100+
Top answer by
Kevin
Coach
Ex-Bain (London) | Private Equity & M&A | 12+ Yrs Experience | The Reflex Method | Free Intro Call
6 Answers
100+ Views
+3
MCK R1
8
on Feb 13, 2026
USA
9
100+
Top answer by
Alessandro
Coach
McKinsey Senior Engagement Manager | Interviewer Lead | 1,000+ real MBB interviews | 2026 Solve, PEI, AI-case specialist
9 Answers
100+ Views
+6
Should I cancel BCG interview R1?
9
on Feb 15, 2026
Europe
8
100+
Top answer by
Soheil
Coach
INSEAD | Strategy Consultant | EM | 5★ Case Interviewer | 50+ Live Case Interviews | 350+ Cases Solved
8 Answers
100+ Views
+5
Mckinsey Interviews
9
on Feb 18, 2026
Middle East
8
100+
Top answer by
Alessandro
Coach
McKinsey Senior Engagement Manager | Interviewer Lead | 1,000+ real MBB interviews | 2026 Solve, PEI, AI-case specialist
8 Answers
100+ Views
E
+5